Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Benefit of chemotherapy in breast cancer depends on estrogen-receptor status

12.04.2006


When it comes to chemotherapy treatment for women whose breast cancer has spread to their lymph nodes, the estrogen status of their tumors matters, says a team of researchers in the April 12 issue of the Journal of the American Medical Association.



Analyzing data from three clinical trials with a total of 6,644 patients, they determined that chemotherapy works much better in breast cancer that is estrogen receptor-negative (ER-) than many people think, and conversely, doesn’t work as well in estrogen receptor-positive (ER+) cancer as believed, says the study’s lead author Donald Berry, Ph.D., chair of the Department of Biostatistics and Applied Mathematics at The University of Texas M. D. Anderson Cancer Center.

This conclusion will come as a surprise to many oncologists, Berry says. Women with "node-positive" breast cancer routinely are given chemotherapy, regardless of their tumor type. Women who have ER+ tumors are also given tamoxifen, a drug which inhibits estrogen use by the cancer cells.


"Our analysis shows that tamoxifen works very well for a number of years and taken as a group, there is little or no benefit of even the cumulative effects of modern improvements in chemotherapy for women with ER+ tumors," he says.

"All in all, this is good news because it shows that the benefit of chemotherapy for ER- tumors is surprisingly dramatic in the same way that tamoxifen’s effect is substantial for ER+ tumors," Berry says.

The research team, which includes investigators from top cancer centers nationwide, studied outcomes from three large randomized clinical trials which tested the optimal use of chemotherapy in node-positive breast cancer. But none of these trials, all of which were conducted by the Cancer and Leukemia Group B and the U.S. Breast Intergroup, considered estrogen status or whether women had received tamoxifen, largely because the diagnostic importance of estrogen status for chemotherapy was not recognized at the time the trials were designed, Berry says.

Accumulated evidence indicates, however, that improvements in chemotherapy disproportionately benefit women with ER- tumors, Berry says; so the research team decided to statistically model the relative contribution of chemotherapy treatment given estrogen receptor status.

They found the absolute benefits due to chemotherapy were greater for patients with ER- tumors compared to those with ER+ tumors. Specifically, 22.8 percent more ER- patients were disease-free after five years if they received chemotherapy versus 7 percent of ER+ patients. The corresponding improvements for overall survival were 16.7 percent versus 4 percent.

The researchers also compared the different chemotherapy regimens tested in the trials, and found the latest chemotherapy combination studied - biweekly doxorubicin/cyclophosphamide plus paclitaxel - lowered the rate of recurrence and death in ER- patients by more than 50 percent, compared to the low-dose regimen used in the first study.

"This tells us that breast oncology has made enormous strides in treating patients with ER- tumors, a finding which contradicts the prevailing wisdom that with the development of tamoxifen and newer selective estrogen receptor modulator drugs, the benefits of medical science have been primarily focused on ER+ tumors," Berry says.

"It is true that tamoxifen changed the landscape for ER+ tumors, but the playing field has now been leveled somewhat given the fact that ER- tumors respond well to modern improvements in chemotherapy regimens," he says.

Nancy Jensen | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Health and Medicine:

nachricht Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center

nachricht Overdosing on Calcium
19.06.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Dry landscapes can increase disease transmission

20.06.2018 | Ecology, The Environment and Conservation

Agrophotovoltaics Goes Global: from Chile to Vietnam

20.06.2018 | Power and Electrical Engineering

Carbon nanotube optics provide optical-based quantum cryptography and quantum computing

19.06.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>